C-KC and RS are funded by the NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s College London. SH is funded by an NIHR Academic Clinical Fellowship. WL is funded by the UK Medical Research Council. The authors declare no conflict of interest in preparing this article.
In recent years, combination strategies (which involve adding additional antidepressants
with a different neurochemical profile) and augmentation (with nonantidepressant drugs such as lithium, T3 Inhibitors,research,lifescience,medical and atypical antipsychotics) are being used more frequently to treat resistant unipolar melancholic depression [Yazici, 2009; Inhibitors,research,lifescience,medical Blier et al. 2010; Ruiz-Doblado et al. 2010]. The use of different combination and augmentation strategies in severe,
resistant depression is based clinically and physiopathologically on the neurochemical complementarity of drugs, their synergies, on the improved tolerability and reduced undesirable effects when a second drug is associated, and also on the growing body of experience with combinations of antidepressants in naturalistic conditions of ‘real’ clinical practice [Rush et al. 2009]. However, the use of the strategy of combining several drugs in resistant diseases also presents a serious predicament in Inhibitors,research,lifescience,medical other areas of medicine (e.g. high-activity towards antiretroviral therapy [HAART], resistant hypertension, etc.). Given that the final objective of antidepressant treatment should be complete remission of the resistant melancholia and not just a simple Inhibitors,research,lifescience,medical response, different observations have endorsed that simultaneous administration of two antidepressants
may produce neurochemical changes more quickly. Case report A 49-year-old woman who had been admitted to hospital with severe melancholia, hypertension on treatment and with a history of six serious melancholic episodes since she was 24 Inhibitors,research,lifescience,medical years old (first puerperium), was treated by our group. She had no previous history of mania or hypomania. The current episode, which was very severe (Beck Depression Inventory [BDI] score: 58) and had a seasonal pattern, was Cilengitide treated first line with a combination of venlafaxine extended release 450 mg + mirtazapine 45 mg + lamotrigine 200 mg daily, resulting in only a poor response in the fourth week (BDI score: 40). This response was manifested essentially at the BDI ITEMS which evaluates symptoms of anxiety, with a scant improvement in qualitatively specific symptoms of mood, thought, speech and psychomotor inhibition. Given the insufficient clinical response and persistence of suicidal ideas, it was decided to change the treatment to clomipramine 375 mg + mirtazapine 45 mg + lithium 800 mg daily + partial sleep deprivation.
Related posts:
- New Job Opening: Mathematical Statistician (Biomedical Research)
- NCCAM Faculty Recruitment through Biomedical Research Core Centers
- The Trick Of Growing To Be A Profitable Pelitinib research Specialist
- In fact a worsening of symptoms has been frequently reported Oth
- Psychopharmacological first-line treatments of anxietydisorders i